Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Free Report) in the 2nd quarter, Holdings Channel reports. The firm acquired 18,027 shares of the company’s stock, valued at approximately $27,000.
Several other institutional investors have also bought and sold shares of the business. Marquette Asset Management LLC bought a new position in Reneo Pharmaceuticals during the first quarter valued at $122,000. Highbridge Capital Management LLC lifted its position in Reneo Pharmaceuticals by 6.5% during the second quarter. Highbridge Capital Management LLC now owns 2,915,376 shares of the company’s stock valued at $4,402,000 after purchasing an additional 178,806 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in shares of Reneo Pharmaceuticals in the 2nd quarter worth about $846,000. Institutional investors own 90.98% of the company’s stock.
Insider Transactions at Reneo Pharmaceuticals
In other news, major shareholder Braden Michael Leonard bought 29,600 shares of the stock in a transaction dated Tuesday, September 24th. The stock was purchased at an average price of $1.41 per share, for a total transaction of $41,736.00. Following the acquisition, the insider now owns 3,388,649 shares of the company’s stock, valued at $4,777,995.09. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders bought 256,239 shares of company stock worth $355,105. 17.90% of the stock is currently owned by insiders.
Reneo Pharmaceuticals Trading Up 5.2 %
Reneo Pharmaceuticals (NASDAQ:RPHM – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. As a group, sell-side analysts predict that Reneo Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.
Reneo Pharmaceuticals Company Profile
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Featured Stories
- Five stocks we like better than Reneo Pharmaceuticals
- What is MarketRank™? How to Use it
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Insider Trades May Not Tell You What You Think
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- RPM International Thrives in Rate-Cut Driven Construction Rally
Want to see what other hedge funds are holding RPHM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Free Report).
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.